Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 107638

Result Summary for 107638

Result Summary

Protocol ID:	107638
Clinical Study ID:	107638
Official Title:	Efficacy, immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV GSK 580299 vaccine in healthy Chinese female subjects
Phase:	phase 3
Study Indications or Diseases:	Human Papillomavirus (HPV)
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Zhu F et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy chinese women aged 18–25 years. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia - 2011 Interim Conference (AOGIN). Bali, Indonesia, 17-19 March 2011. Zhu FC et al. Efficacy and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN), Hong Kong, 13-15 July 2012. Zhao F-H et al. Prevalence and type distribution in healthy Chinese women aged 18-25 years from a clinical trial. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN), Hong Kong, 13-15 July 2012.